HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use CIBINQO safely and effectively. See full prescribing information for CIBINQO.
CIBINQO™ (abrocitinib) tablets, for oral use
Initial U.S. Approval: 2022
WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE), and THROMBOSIS
If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.